SETD2 expression was also correlated with many features of tumor progression, including histological grade, clinical TNM stage, and invasion depth (T stage), which implied that low SETD2 expression was associated with high histological grade, clinical TNM stage, and T stage (Fig. 1B–D). The gene discussed is SETD2; the disease is neoplasm.